Status:
UNKNOWN
Prognostic Role of Platelet _lymphocyte and Neutrophil _monocyte in CLL
Lead Sponsor:
Assiut University
Conditions:
CLL Progression
Eligibility:
All Genders
Brief Summary
The biological rationale in calculating PLR stems from the increase in the lymphocyte count and reduction in the platelet count often encountered in the advances stages of CLL .NMR median value was si...
Detailed Description
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the western world. In Egypt, CLL is the most common subtype of leukemias * the National Cancer Registry reported over 80% of ...
Eligibility Criteria
Inclusion
- \- All CLL patients
Exclusion
- CLL patients on treatment
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04811950
Start Date
June 1 2022
End Date
October 1 2023
Last Update
March 23 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.